Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitam...

Descripción completa

Detalles Bibliográficos
Autores principales: Belada, David, Kopeckova, Katerina, Bergua Burgues, Juan Miguel, Stevens, Don, André, Marc, Persona, Ernesto Perez, Pichler, Petra, Staber, Philipp B., Trneny, Marek, Duell, Johannes, Waldron-Lynch, Maeve, Wagner, Steve, Mukhopadhyay, Amitava, Dirnberger-Hertweck, Maren, Burke, John M., Nowakowski, Grzegorz S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651865/
https://www.ncbi.nlm.nih.gov/pubmed/37369099
http://dx.doi.org/10.1182/blood.2023020637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651865/
https://www.ncbi.nlm.nih.gov/pubmed/37369099
http://dx.doi.org/10.1182/blood.2023020637

Ejemplares similares